Summit Therapeutics

SMMTPhase 3

Oxford, United KingdomFounded 2003summittxplc.com

Summit Therapeutics is a clinical-stage biopharmaceutical company developing novel therapeutics with a focus on oncology and infectious diseases. The company has built a pipeline of innovative drug candidates and maintains strategic partnerships to advance its clinical programs. With a market valuation of approximately $12 billion, Summit represents a significant player in the biotechnology sector.

Market Cap

$12.0B

Founded

2003

Focus

Biotech

SMMT · Stock Price

USD 15.51+12.67 (+446.13%)

Historical price data

AI Company Overview

Technology Platform

Clinical-stage biopharmaceutical company developing small molecule and biologic therapeutics targeting critical pathways in oncology and infectious diseases.

Pipeline Snapshot

27 drugs in pipeline, 5 in Phase 3

Drug	Indication	Stage
Ivonescimab Injection + Pembrolizumab Injection	Non-Small Cell Lung Cancer	Phase 3
Ridinilazole + Vancomycin	Clostridioides Difficile Infection	Phase 3
Drug: Ivonescimab Injection + Drug: Bevacizumab Injection	Metastatic Colorectal Cancer (CRC)	Phase 3
Ivonescimab Injection + Pembrolizumab Injection	Non-Small Cell Lung Cancer	Phase 3
Ridinilazole + Vancomycin	Clostridioides Difficile Infection	Phase 3

Funding History

Total raised: $30M

Series A$30MUndisclosedJun 15, 2015

IPOUndisclosedUndisclosedJun 15, 2015

Opportunities

Summit has opportunities to advance its clinical pipeline in high-value therapeutic areas with significant unmet medical needs.

The company's public status provides access to capital markets for funding continued development.

Risk Factors

Key risks include clinical trial failures, regulatory delays, competitive pressures, and ongoing funding requirements typical of clinical-stage biotechnology companies.

Market volatility could also impact access to capital.

Competitive Landscape

Summit competes in highly competitive oncology and infectious disease markets against both large pharmaceutical companies and specialized biotechnology firms. Differentiation comes from specific drug candidates and target selection strategies.

Publications

Patents

Pipeline